Pasar al contenido principal

INHIBIDORES DE DREAM, PROCESAMIENTO DE ATF6 Y PERDIDA COGNITIVA EN AD

SAF2017-89554-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Fine-tuning DREAM signaling using chemical tools for neurodegenerative disease treatment

  • Gutiérrez-Rodríguez, Marta
  • Cercós, Pilar
  • Izquierdo García, Carolina
  • Peraza, Diego A.
  • López-Hurtado, Alejandro
  • González Pérez, Paz
  • Dopazo, Xose M.
  • Herranz, Rosario
  • González, Teresa
  • Mellström, Britt
  • Martín-Martínez, Mercedes
  • Naranjo, José Ramón
  • Valenzuela, Carmen
Resumen del trabajo presentado al 6th European Chemical Biology Symposium ECBS/LS-EuChemS, celebrado en Madrid (España) del 3 al 5 de abril de 2019., DREAM (Downstream Regulatory Element Antagonist Modulator), also known as KChIP-3 or calsenilin, is a multifunctional calcium binding protein that controls the expression level and/or the activity of several proteins related to calcium homeostasis, neuronal excitability and neuronal survival. As an auxiliary protein in the plasma membrane, DREAM interacts with, and regulates, the gating of KV4 potassium channels, L- and T-type voltage-dependent calcium channels, NMDA receptors and the transcriptor factor ATF6, which is involved in the unfolding protein response machinary. Considering that altered neuronal calcium homeostasis and the accumulation of poorly folded proteins are common features of many neurodegenerative pathologies, the DREAM modulation could open new avenues for the treatment of neurodegenerative diseases. We recently showed that reduced DREAM expression or blockade of DREAM activity by repaglinide is neuroprotective in Huntington's disease (HD)[1]. However, up to now, only three DREAM binding molecules have been identified. Hence, there is a clear need for the development of chemical tools to modulate and characterize DREAM activity and its interactions. In this communication we will report the identification of novel DREAM modulators by following a multidisciplinary strategy that involves structure-based design, organic chemistry, site-directed mutagenesis and in vitro and in vivo experiments. Our findings open a new avenue in the search of effective treatments of neurodegenerative diseases., Spanish Ministery of Economy, Industry and Competitivity (AEI-FEDER, EU grants): BFU2015-67284-R, SAF2017-89554-R, SAF2016-75021-R, SAF2015-66275-C2-2-R; Instituto de Salud Carlos III CIBERNED and CIBERCV programs; the Madrid regional government/Neurodegmodels; and CSIC PIE 201580E073., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Identification of IQM-266, a novel DREAM ligand that modulates Kv4 currents

  • Peraza, Diego A.
  • Cercós, Pilar
  • Miaja, Pablo
  • Merinero, Yaiza G.
  • Lagartera, Laura
  • Socuéllamos, Paula G.
  • Izquierdo García, Carolina
  • Sánchez, Sara A.
  • López-Hurtado, Alejandro
  • Martín-Martínez, Mercedes
  • Olivos-Oré, Luis Alcides
  • Naranjo, José Ramón
  • Artalejo, Antonio R.
  • Gutiérrez-Rodríguez, Marta
  • Valenzuela, Carmen
Resumen del trabajo presentado al VII Congreso Red Española Canales Iónicos: Symposium 6: Drug Discovery and ion channel Pharmacology, celebrado en Cáceres del 15 al 17 de mayo de 2019., Funded by BFU2015-67284-R (to MG-R), SAF2014-53412-R and SAF2017-89554-R (to JN), SAF2013-45800-R, SAF2016-75021-R (to CV), SAF2015-66275-C2-2-R (to MM-M); UCM grant: PR75/18-21593 (to AA); and CSIC grants: PIE 201820E104 (to CV) and 201880E109 (to MG-R and MM-M)., Peer Reviewed